FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206064113> ?p ?o ?g. }

• W3206064113 endingPage "327" @default.
• W3206064113 startingPage "312" @default.
• W3206064113 abstract "Since December 2019, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has exploded and led to a global crisis. Currently, the global case numbers topped 200 million, and toll of dead exceeded 4 million around the world. The pathogenesis of coronavirus disease 2019 (COVID-19) is driven by two processes. During the first stage of the infection that lasts around 5-7 days, replication of SARS-CoV-2 occurs. In the second stage, the disease may progress due to an exaggerated inflammatory response leading to tissue damage. Therefore, it is anticipated that antiviral agents would be effective during the early phase of the disease, while immunomodulator agents are likely to be more beneficial in the second stage of COVID-19. This basic concept of disease development led to explore several antiviral and immunomodulator agents for the treatment of COVID-19. Currently, remdesivir is the only available Food and Drug Administration-approved antiviral agent for the treatment of COVID-19. However, some other agents have been approved by various mechanisms, including Emergency Use Authorizations, Emergency Investigational New Drug applications, compassionate use or expanded access programs. In addition, a variety of repurposed agents that were approved for other indications are being investigated for the treatment of COVID19 in clinical trials. A myriad of publications including randomized controlled trials (RCTs) are emerging continuously and are accessible as peer-reviewed, pre-print and press release formats. Considering the critical importance of RCTs in generating evidence and providing further guidance on COVID-19 treatment, we herein reviewed only RCTs and meta-analyses. The discussion includes antiviral agents (hydroxychloroquine, lopinavir/ritonavir, remdesivir, favipiravir and ivermectin) and, various immunomodulatory drugs (corticosteroids, tocilizumab, baricitinib, and IL-1 inhibitors). Other investigational therapies including darunavir/cobicistat, umifenovir, sofosbuvir/daclatasvir, sofobuvir/ledipasvir, ribavirin, nitazoxanide and interferon-based regimens were not evaluated due to insufficient data on the efficacy and safety of these agents." @default.
• W3206064113 created "2021-10-25" @default.
• W3206064113 creator A5054863331 @default.
• W3206064113 creator A5085358849 @default.
• W3206064113 date "2021-09-01" @default.
• W3206064113 modified "2023-09-30" @default.
• W3206064113 title "Current status of therapeutic alternatives for COVID-19: A narrative review" @default.
• W3206064113 cites W1959216194 @default.
• W3206064113 cites W201127736 @default.
• W3206064113 cites W2012188043 @default.
• W3206064113 cites W2060514161 @default.
• W3206064113 cites W2061777515 @default.
• W3206064113 cites W2166189758 @default.
• W3206064113 cites W2255243349 @default.
• W3206064113 cites W2617680249 @default.
• W3206064113 cites W3005212621 @default.
• W3206064113 cites W3008028633 @default.
• W3206064113 cites W3008526620 @default.
• W3206064113 cites W3008827533 @default.
• W3206064113 cites W3010673910 @default.
• W3206064113 cites W3011610993 @default.
• W3206064113 cites W3012379316 @default.
• W3206064113 cites W3012655019 @default.
• W3206064113 cites W3014003872 @default.
• W3206064113 cites W3014199470 @default.
• W3206064113 cites W3014364276 @default.
• W3206064113 cites W3014962324 @default.
• W3206064113 cites W3016395404 @default.
• W3206064113 cites W3017382320 @default.
• W3206064113 cites W3023606094 @default.
• W3206064113 cites W3025316553 @default.
• W3206064113 cites W3025795175 @default.
• W3206064113 cites W3027630905 @default.
• W3206064113 cites W3032373213 @default.
• W3206064113 cites W3032677067 @default.
• W3206064113 cites W3032915827 @default.
• W3206064113 cites W3034660339 @default.
• W3206064113 cites W3036398841 @default.
• W3206064113 cites W3042033822 @default.
• W3206064113 cites W3042228553 @default.
• W3206064113 cites W3043399375 @default.
• W3206064113 cites W3044118599 @default.
• W3206064113 cites W3045220852 @default.
• W3206064113 cites W3048510827 @default.
• W3206064113 cites W3060275525 @default.
• W3206064113 cites W3067080207 @default.
• W3206064113 cites W3080718665 @default.
• W3206064113 cites W3080857519 @default.
• W3206064113 cites W3081721922 @default.
• W3206064113 cites W3081877184 @default.
• W3206064113 cites W3082108964 @default.
• W3206064113 cites W3082355253 @default.
• W3206064113 cites W3083605260 @default.
• W3206064113 cites W3090929175 @default.
• W3206064113 cites W3091148819 @default.
• W3206064113 cites W3091868035 @default.
• W3206064113 cites W3093604087 @default.
• W3206064113 cites W3093837118 @default.
• W3206064113 cites W3094197937 @default.
• W3206064113 cites W3094609299 @default.
• W3206064113 cites W3098266159 @default.
• W3206064113 cites W3102453076 @default.
• W3206064113 cites W3103598365 @default.
• W3206064113 cites W3104688112 @default.
• W3206064113 cites W3107056972 @default.
• W3206064113 cites W3109912694 @default.
• W3206064113 cites W3110466220 @default.
• W3206064113 cites W3110844195 @default.
• W3206064113 cites W3111068209 @default.
• W3206064113 cites W3111949621 @default.
• W3206064113 cites W3112115637 @default.
• W3206064113 cites W3113196149 @default.
• W3206064113 cites W3113301094 @default.
• W3206064113 cites W3117275749 @default.
• W3206064113 cites W3118761418 @default.
• W3206064113 cites W3121693389 @default.
• W3206064113 cites W3126722533 @default.
• W3206064113 cites W3127381644 @default.
• W3206064113 cites W3129869280 @default.
• W3206064113 cites W3130126061 @default.
• W3206064113 cites W3134674969 @default.
• W3206064113 cites W3135420706 @default.
• W3206064113 cites W3142505488 @default.
• W3206064113 cites W3156297617 @default.
• W3206064113 cites W3159503438 @default.
• W3206064113 cites W3167671574 @default.
• W3206064113 cites W3176756284 @default.
• W3206064113 cites W3182422976 @default.
• W3206064113 cites W3183356099 @default.
• W3206064113 cites W3189881092 @default.
• W3206064113 cites W3198379317 @default.
• W3206064113 cites W4206449744 @default.
• W3206064113 cites W4210642183 @default.
• W3206064113 cites W4253143966 @default.
• W3206064113 doi "https://doi.org/10.53854/liim-2903-2" @default.
• W3206064113 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35146336" @default.
• W3206064113 hasPublicationYear "2021" @default.
• W3206064113 type Work @default.

• next